Your session is about to expire
← Back to Search
Pembrolizumab + Carboplatin + Paclitaxel for Epithelial Ovary Cancer
Study Summary
This trial is testing a new combination of drugs to see if it can improve progression-free survival in ovarian cancer patients who haven't responded well to other treatments.
- Ovarian Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a current or past history of active tuberculosis.You have cancer that has spread to your brain or the tissues covering your brain and spinal cord.You have a current infection that needs strong medication to treat.You have advanced stage ovarian, fallopian tube, or peritoneal cancer.You have a weakened immune system or are taking strong medications that lower your immune system's ability to fight off infections.You are allergic to pembrolizumab or any of its ingredients.You have received a specific type of cancer treatment within the last 4 weeks, or you have not fully recovered from side effects of a previous treatment.You have received chemotherapy, targeted small molecule therapy, or radiation therapy within the past 2 weeks, or have not fully recovered from side effects of previous treatments.You have been diagnosed with another type of cancer in the past 3 years that is still growing or needs treatment.You have an ongoing autoimmune disease that needed strong medication in the past 2 years.You have been treated with a specific type of medication that targets the immune system.You have a current, active infection of Hepatitis B or Hepatitis C.You have been diagnosed with HIV.You have certain types of ovarian or fallopian tube cancers that have come back or are at an early stage.You have had a lung inflammation that needed steroids in the past, or you currently have lung inflammation.You have remaining cancer after surgery, or you have visible cancer based on specific guidelines.You should be able to carry out everyday activities without any major issues.
- Group 1: Chemotherapy combined with pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are being welcomed into this clinical trial?
"As of now, this clinical trial is not looking for new patients to participate. The study was originally posted on October 1st, 2016 and was last edited on April 7th, 2022. There are currently 702 other trials actively enrolling patients with ovarian cancer and 2076 Pembrolizumab studies searching for participants."
Has Pembrolizumab been federally approved in the USA?
"Pembrolizumab's safety is based on data from Phase 2 trials, meaning that while there is some evidence to support its safety, there is no clinical data yet supporting its efficacy."
What other scientific papers have been published on Pembrolizumab?
"Pembrolizumab is being studied in 2076 different trials, with 424 of those currently active. The great majority of these are Phase 3 studies. Most of the research is based out of Shanghai however there are 92200 locations running Pembrolizumab trials."
What are the chief indications for Pembrolizumab?
"Pembrolizumab is often used to treat malignant neoplasms, but it can also be useful in treating other conditions like unresectable melanoma and high risk of recurrence."
Can new patients still join this research project?
"This particular clinical trial is no longer recruiting patients. The study was created on October 1st, 2016 but has not been updated since April 7th, 2022. There are currently 702 and 2076 studies respectively for ovarian cancer and Pembrolizumab that are actively looking for participants."
Share this study with friends
Copy Link
Messenger